Sugi Predict

Sugi Predict / Compounds / SCHEMBL35185

SCHEMBL35185

SCHEMBL35185

CN(C)S(=O)(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.65
▸ KMT2A Q03164 5/20 0.65
▸ RAB9A P51151 3/20 0.58
▸ ALDH1A1 P00352 7/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ NPC1 O15118 2/20 0.58
▸ TP53 P04637 1/20 0.58
▸ LMNA P02545 5/20 0.57
▸ HTT P42858 2/20 0.57
▸ MAPT P10636 1/20 0.57
▸ AKR1B1 P15121 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ F2 P00734 1/20 0.53
▸ PRSS1 P07477 1/20 0.53
▸ PRSS2 P07478 1/20 0.53
▸ PRSS3 P35030 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29399627 1.00 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL3653439 0.86 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL14221053 0.85 F2 (0.56) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL20790417 0.85 LMNA (0.52) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL2848307 0.84 MEN1 (0.63) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL2005622 0.84 MEN1 (0.63) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL3938764 0.83 SMN1; SMN2 (0.53) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL8241614 0.83 ALDH1A1 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL17275120 0.83 F2 (0.55) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL4132126 0.83 NPC1 (0.54) MEN1KMT2ARAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
US-12509446-B2 FYN and VEGFR2 kinase inhibitors ROTTAPHARM BIOTECH S.R.L. (IT) 2025-12-30 — — US disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 — — US disclosed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 — — EP disclosed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 — — EP disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20050171092-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2005-08-04 — — US disclosed
EP-1274701-B1 [1,4']-BIPIPERIDINE COMPOUNDS ASTRAZENECA AB (SE) 2005-06-29 — — EP disclosed
US-6903115-B2 Bipiperidine compounds ASTRAZENECA AB (SE) 2005-06-07 — — US disclosed
EP-1493743-A1 Substituted bipiperidine intermediates and derivatives thereof AstraZeneca AB (SE) 2005-01-05 — — EP disclosed
US-20040014783-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-22 — — US disclosed
US-20040006080-A1 Chemical compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2004-01-08 — — US disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 — — US disclosed
EP-1274701-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-01-15 — — EP disclosed
US-20020077337-A1 Chemical compounds ASTRAZENECA AB (SE) 2002-06-20 — — US disclosed
WO-2001077101-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MEN1 1366/4885KMT2A 792/4885RAB9A 572/4885
US-12509446-B2 FYN and VEGFR2 kinase inhibitors FYN, LCK, LYN MEN1 4110/4885KMT2A 1655/4885RAB9A 1854/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 MEN1 4097/4885KMT2A 1593/4885RAB9A 1826/4885
US-20020077337-A1 Chemical compounds CCR3, CCR1, CCR4 MEN1 696/4885KMT2A 3084/4885RAB9A 2344/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 MEN1 4097/4885KMT2A 1593/4885RAB9A 1826/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB MEN1 1366/4885KMT2A 792/4885RAB9A 572/4885
US-20050171092-A1 Chemical compounds CCR3, CCR1, CCR4 MEN1 809/4885KMT2A 2792/4885RAB9A 2189/4885
US-20040006080-A1 Chemical compounds CCR3, CCR1, CCR4 MEN1 696/4885KMT2A 3084/4885RAB9A 2344/4885
US-20040014783-A1 Chemical compounds CCR3, CCR1, CCR4 MEN1 696/4885KMT2A 3084/4885RAB9A 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.